Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | EEF2K | O00418 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31220065 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL31378833 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL5469217 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL23562902 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL29791251 | 0.96 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL5464319 | 0.96 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL13970864 | 0.76 | GRIN2D (0.34) | ADRA2AADRA2BADRA2C | |
| SCHEMBL2666127 | 0.74 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL14918240 | 0.74 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL20178519 | 0.74 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4426690-A2 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081367-A2 | 2-AMINO IMIDAZOLE DERIVATIVES | Mirati Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081367-A2 | 2-AMINO IMIDAZOLE DERIVATIVES | Mirati Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2012156284-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012126791-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| WO-2010026771-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF, AND BACTERICIDAL AGENT FOR AGRICULTURAL OR HORTICULTURAL APPLICATIONS | 日本曹達株式会社 (JP) | 2010-03-11 | — | — | WO | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1954132-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2005097806-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6777426-B2 | SELECTIVE AGONISTS FOR HUMAN ALPHA 2 ADRENERGIC RECEPTORS; TREATING PAIN, MIGRAINE, HEADACHES, GLAUCOMA; 2-(INDAN-5-YL)AMINO-2-IMIDAZOLINE FOR EXAMPLE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0556008-B1 | Condensed imidazopyridine derivatives with psychotropic activity | SHIONOGI & CO (JP) | 1997-05-14 | — | — | EP | disclosed |
| US-5461062-A | Psychotropic agent as antianxiety agent, anesthesia antagonistic agent | SHIONOGI & CO., LTD. (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5378848-A | Benzodiazepine agonist, psychotropic, antianxiety, cerebral function activator, anesthesia atagonist | SHIONOGI & CO., LTD. (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0556008-A1 | Condensed imidazopyridine derivatives with psychotropic activity | SHIONOGI & CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ADRA2A 3930/4885ADRA2B 3351/4885ADRA2C 2275/4885 |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | ADRA2A 4/4885ADRA2B 6/4885ADRA2C 2/4885 |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ADRA2A 2080/4885ADRA2B 2507/4885ADRA2C 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.